Transcode therapeutics stock.
Corporate Profile. TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. TransCode’s proprietary platform, TTX, repurposes an iron oxide nanoparticle that has been extensively used for imaging to solve for RNA delivery in oncology.
In connection with the reverse stock split, the Company's CUSIP number will change to 89357L 204 as of 4:05 pm on Monday, May 22, 2023. About TransCode Therapeutics9 thg 6, 2023 ... (Nasdaq: RNAZ) on its registered direct offering of an aggregate of 2,000,000 shares of its common stock, together with accompanying common ...A. While ratings are subjective and will change, the latest TransCode Therapeutics ( RNAZ) rating was a reiterated with a price target of $0.00 to $3.00. The current price TransCode Therapeutics ...Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00.A. While ratings are subjective and will change, the latest TransCode Therapeutics ( RNAZ) rating was a reiterated with a price target of $0.00 to $3.00. The current price TransCode Therapeutics ...Insider Activity at TransCode Therapeutics. In other TransCode Therapeutics news, CFO Thomas A. Fitzgerald acquired 49,350 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was bought at an average price of $0.51 per share, with a total value of $25,168.50.
Dec 1, 2023 · 1 brokerages have issued 12 month price objectives for TransCode Therapeutics' stock. Their RNAZ share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 4,976.1% from the stock's current price. AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ...
With TransCode Therapeutics delivering positive pre-clinical results for its brain tumor candidate, RNAZ stock soared on the implications.More From InvestorPlace Musk’s “Project Omega” May ...25 thg 9, 2023 ... TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, ...TransCode Therapeutics Inc (NASDAQ:RNAZ) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest ...TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously …
TransCode Therapeutics stock is falling hard on Tuesday after the medical company announced a public offering for RNAZ shares. Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers ...
The Wall Street analyst predicted. that Transcode Therapeutics's share price could reach $3.00 by Oct 24, 2024. The average Transcode Therapeutics stock price prediction forecasts a potential upside of 1,150% from the current RNAZ share price of $0.24.
26 thg 9, 2023 ... Use of technology ... TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug ...Dec 4, 2023 · TransCode Therapeutics hasn’t yet revealed details of the proposed public stock offering. RNAZ Trading at -49.61% from the 50-Day Moving Average After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.06% of loss for the given period. Get the latest Galera Therapeutics Inc (GRTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common ...Nov 17, 2023 · Transcode Therapeutics Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-5.570 per share for the current fiscal year. Transcode Therapeutics Inc does not currently pay a dividend.
Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...Oct 26, 2023 · TransCode Therapeutics Announces Public Offering of Common Stock. October 26, 2023. PDF Version. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an ... The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full …Get the latest Transcode Therapeutics Inc (RNAZ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
The stock price for . TransCode Therapeutics (NASDAQ: RNAZ) is $0.2301 last updated Today at December 1, 2023 at 5:07 PM UTC. Q Does TransCode Therapeutics (RNAZ) pay a dividend?TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...
TransCode Therapeutics Announces Pricing of $8 Million Public Offering. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology ...Find the latest historical data for TransCode Therapeutics, Inc. Common Stock (RNAZ) at Nasdaq.com.BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to ...Dec 1, 2023 · TransCode Therapeutics ... it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 a piece in ... BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...Transcode Therapeutics Inc stock performance at a glance. Check Transcode Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Shares of TransCode Therapeutics jumped Monday after reporting positive study results for its lead cancer treatment candidate. The stock was up 96% at $1.30 in …BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...
Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...
Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per ...
9 thg 6, 2023 ... (Nasdaq: RNAZ) on its registered direct offering of an aggregate of 2,000,000 shares of its common stock, together with accompanying common ...TransCode Therapeutics stock is falling hard on Tuesday after the medical company announced a public offering for RNAZ shares. Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers ...On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 ...Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...TransCode Therapeutics, Inc. BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA ...TransCode Therapeutics (NASDAQ: RNAZ) stock is rocketing higher on Wednesday after the company withdrew a stock offering. This comes from a filing with the U.S. Securities and Exchange Commission ...Oncology firm TransCode Therapeutics prices 6.25M-share IPO at $4. Get the latest news and real-time alerts from TransCode Therapeutics, Inc. (RNAZ) stock at Seeking Alpha.TransCode Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.00. See the top stocks recommended by analysts >> Tarsus Pharmaceuticals (TARS)Dec 1, 2023 · TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ... BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief that current ...Dec 7, 2022 · TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ... Among that is what’s moving shares of Safe & Green (NASDAQ: SGBX), TransCode Therapeutics (NASDAQ: RNAZ) and Tharimmune (NASDAQ: THAR) stock today. All of that news is available at the links below!
Mar 31, 2023 · TransCode expects that its cash of approximately $5.0 million as of December 31, 2022, together with approximately $1.3M in net proceeds received from the sale of common stock in its February 2023 registered direct offering and $871 thousand of additional funding expected in the second quarter of 2023 for the third year of its SBIR award will ... Follow. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics ...Transcode Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The ...First Quarter 2022 Financial Highlights. Cash and cash equivalents were $16.9 million at March 31, 2022, compared to $20.8 million at December 31, 2021. Research and development expense was $1.9 ...Instagram:https://instagram. carnival cruise stock prices todaynvdy stocktd ameritrade interest rate on casht.g.b TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA ... flot stockpeacock stock prices The 1-for-20 reverse stock split will automatically convert 20 current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in connection ...BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ... tom brady auto card TSLA Tesla, Inc. Common Stock $230.05 +0.01 BETR Better Home & Finance Holding Company Class A Common Stock $1.56 +0.41 +35.65% Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the...Oncology firm TransCode Therapeutics prices 6.25M-share IPO at $4. Get the latest news and real-time alerts from TransCode Therapeutics, Inc. (RNAZ) stock at Seeking Alpha.